OTC Markets EXMKT - Delayed Quote USD
NovAccess Global Inc. (XSNX)
0.0002
+0.0001
+(100.00%)
At close: June 5 at 8:00:00 PM EDT
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Dwain K. Morris-Irvin M.P.H., MPH, Ph.D. | CEO, Interim Principal Financial Officer & Director | 155.43k | -- | 1968 |
| Dr. Christopher Wheeler Ph.D. | President of Stemvax Therapeutics | -- | -- | -- |
NovAccess Global Inc.
8584, Washington Street
Suite 127
Chagrin Falls, OH 44023
United States
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 3
Description
NovAccess Global Inc., a biopharmaceutical company, develops novel immunotherapies to treat brain tumor patients in the United States. It specializes in cutting-edge research related to utilizing a patient's immune system to attack the cancer. The company was incorporated in 1997 and is headquartered in Chagrin Falls, Ohio.
Corporate Governance
NovAccess Global Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
June 23, 2025 at 8:00 PM UTC - July 8, 2025 at 8:00 PM UTC
NovAccess Global Inc. Earnings Date
Recent Events
April 24, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
Related Tickers
ASNHF AVIDUS MANAGEMENT GROUP
0.0011
0.00%
MTST MetaStat, Inc.
0.0001
-50.00%
AMBS Amarantus BioScience Holdings, Inc.
0.0001
-66.67%
EVLO Evelo Biosciences, Inc.
0.0005
0.00%
MBCOF Marvel Biosciences Corp.
0.0700
-11.28%
VAXX Vaxxinity, Inc.
0.0001
0.00%
PMCB PharmaCyte Biotech, Inc.
1.0400
+1.96%
PBLA Panbela Therapeutics, Inc.
0.2419
-0.45%
GYRE Gyre Therapeutics, Inc.
8.50
+1.07%
PHRRF PharmaTher Holdings Ltd.
0.1480
-7.50%